

Pakistan Veterinary Journal

ISSN: 0253-8318 (PRINT), 2074-7764 (ONLINE) Accessible at: www.pvj.com.pk

# SHORT COMMUNICATION

# Mannan oligosaccharide supplementation during gestation can enhance porcine reproductive and respiratory syndrome virus (PRRS)-specific antibody levels of sows and their piglets

Sarthorn Porntrakulpipat<sup>1,2\*</sup>, Yaowapa Tuangtananan<sup>5</sup>, Sutisa Choosing<sup>5</sup>, Nontawit Yochai<sup>5</sup>, Pittaya Papirom<sup>3</sup>, Jatesada Jiwakanon<sup>1,2</sup>, Peerapol Sukon<sup>1,4</sup>, Wilairat Chumsing<sup>6</sup>, Orawan Boodde<sup>6</sup> and Worawidh Wajjwalku<sup>7</sup>

<sup>1</sup>Research Group for Preventive Technology in Livestock; <sup>2</sup>Department of Veterinary Medicine; <sup>3</sup>Department of Pathobiology; <sup>4</sup>Department of Anatomy; <sup>5</sup>Faculty of Veterinary Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand; <sup>6</sup>Department of Farm Resources and Production Medicine; <sup>7</sup>Department of Veterinary Pathology, Faculty of Veterinary Medicine, Kasetsart University, Kamphaengsaen Nakhonpathom 73140, Thailand \*Corresponding author: sarthorn@kku.ac.th

### ARTICLE HISTORY (14-590)

Received:November 21, 2104Revised:June 12, 2015Accepted:July 04, 2015Online available:August 26, 2015Key words:Humoral immunityMannan oligosaccharidePRRS

# ABSTRACT

PRRS vaccination is widely used to induce humoral and cell-mediated protective immune (CMI) responses. However, vaccination alone is often insufficient to induce protective immunity. Mannan oligosaccharide (MOS), the outer cell wall of yeast, is known to potentiate both cell-mediated and humoral immunity. This study aimed to evaluate the potentiating effect of MOS on the PRRS-specific antibody production in the sows and subsequent antibody transfer to their offspring. Thirsty seven sows were randomly assigned to 3 experimental groups: control, supplementation of 400 and 800 ppm MOS in feed during gestation. The PRRS-specific antibody in the sera of sows and their piglets were measured one day before and after parturition, respectively. The results showed that at 400 ppm MOS as feed additive for sows were effectively enhance PRRS-specific antibodies (by ELISA S/P ratio) but not for neutralizing antibody. At 800 ppm MOS in sows' feed, significantly increase of neutralizing antibody was showed. In conclusion, supplementation of MOS in sows' feed would be helpful to strengthen the effect of PRRS vaccination.

©2015 PVJ. All rights reserved

**To Cite This Article:** Porntrakulpipat S, Tuangtananan Y, Choosing S, Yochai N, Papirom P, Jiwakanon J, Sukon P, Chumsing W, Boodde O and Wajjwalku W, 2016. Mannan oligosaccharide supplementation during gestation can enhance porcine reproductive and respiratory syndrome virus (PRRS)-specific antibody levels of sows and their piglets. Pak Vet J, 36(1): 106-108.

# INTRODUCTION

Mannan oligosaccharide (MOS), the outer cell wall of yeast, has been used as a growth promotant as an alternative of antibiotics. Also, their modulating immune response in animals has been demonstrated (Che *et al.*, 2011). Recently, Zanello *et al.* (2013) showed that administration of yeast to sows during late gestation and lactation could induce the increase of total IgG level in colostrum and milk.

Porcine reproductive and respiratory syndrome (PRRS) causes major economic loss in swine industry worldwide (Neumann *et al.*, 2005). Management practices and elimination programs have been applied to reduce and eliminate PRRSV challenge. However, due to the high investment costs, not all of pig farms could afford those valuable measures. Instead, they use the PRRSV vaccination as an alternative measure (Charerntantanakul, 2012).

Series of experiments in sows (Osorio *et al.*, 2002) and piglets (Lopez *et al.*, 2007) showed that passive transfer of the immune sera can render sufficient NA titer to protect against the homologous challenge and the transplacental infection of PRRSV. Therefore, vaccination at late gestation plus supplementation of MOS (Actigen®) during gestation period would allow effective transfer of protective immunity and enhance the protective effects of PRRSV vaccination to their piglets.

## MATERIALS AND METHODS

Thirty seven crossbred sows (Large White x Landrace) from commercial pig farms near Khon Kaen University which considered stable according to their sample to positive S/P ratio were used in this study. This farm had previous experience of type 2 PRRSV outbreaks and has been using a commercial type 2 modified live

virus (MLV) for vaccination. Only sows of the parity 2 to 6 were randomly assigned to 3 treatment groups: Control group (n=10) received gestation diets without supplement; 400MOS group (n=14) received gestation diets supplemented with 400 ppm MOS and 800MOS group (n=13) received gestation diets supplemented with 800 ppm MOS.

The treatment started from day 42 of gestation until parturition. The amounts of diet were adjusted according to the body condition and the parity of sows. All sows received modified live PRRS vaccine (Boehringer Ingelheim) on day 55 of the gestation and 2 weeks later.

Blood samples from sows were collected from ear vein one day before parturition. Three biggest and 3 smallest piglets (by body weight) from each litter were selected for blood collection 1 day after birth.

A commercial ELISA kit for PRRSV antibody test (IDEXX PRRS X3 Ab Test) was used to detect PRRSV specific antibodies. According to the manufacturer's instruction, sample to positive control (S/P) ratio of >0.4 was considered positive. Serum neutralizing (SN) titers were performed as described previously (Geldhof *et al.*, 2012). Neutralizing antibody titers were expressed as the reciprocal of the highest serum dilution in which no cytopathic effect (CPE) was observed. Each sample was run in triplicate.

Ten serum samples from piglets (2 from control, 3 from 400MOS and 5 from 800MOS groups) and 2 serum samples from sows (from 800MOS groups) were excluded due to hemolysis.

The SN titers were evaluated as continuous variables after log<sub>2</sub> transformation of the raw titers. Difference of SN titers and S/P ratio between groups was evaluated by Analysis of Variance (ANOVA). Difference between each pair was then analyzed using Turkey's t-test. Chi-square test was used for analysis of dichotomous data (the number of positive pigs at the cut-off value 1:32). Statistical differences were declared at P<0.05.

### RESULTS

The MOS-treated sows showed relatively higher S/P ratio than those in the control group, although the significant differences of S/P ratio were not observed (P>0.05). The S/P ratio of 400MOS group was slightly higher than that of 800MOS group but statistically no significant difference between them (Table 1). Piglets obtained from MOS-treated groups had significantly higher S/P ratio (P<0.05) than those from the control group. The piglets derived from the sows of 400MOS group showed higher S/P ratio than those obtained from sows of 800MOS group, although statistically no significant difference between them (Table 1).

For SN titers, the sows in the 800MOS group showed higher SN titers than those in the control or 400MOS group, although statistically no significant difference between each group (Table 2). The piglets obtained from the sows in the 800MOS group showed significantly higher SN titers than those obtained from sows in the 400MOS group or from the sows in the control group (Table 2). No difference was observed for the SN titers of the piglets from the sows of 400MOS group and from the control group.

Table I: ELISA S/P ratio of the sows and their piglets

	S/P ratio (Mean±SD)					
Treatment	Sows	Piglets				
Control	0.62±0.45 (n=10)	1.45±0.67ª (n=58)				
400 MOS	1.37±0.95 (n=14)	2.01±0.92 <sup>b</sup> (n=81)				
800 MOS	1.17±0.96 (n=11)	1.80±1.02 <sup>b</sup> (n=73)				

Different superscript letters in the same column indicate significant differences between treatments (P<0.05).

Table 2: SN titers of sows and their piglets

	Log <sub>2</sub> SN titers (Mean±SD)					
Treatments	Sows	Piglets				
Control	2.8±1.5 (n=10)	4.2±1.8ª (n=58)				
400 ppm MOS	2.6±1.3 (n=14)	4.9±1.9ª (n=81)				
800 ppm MOS	4.1±2.2 (n=11)	5.1±2.3 <sup>b</sup> (n=73)				
Different superscript	letters associated in the	same column indicate				

significant differences between treatments (P<0.05).

**Table 3:** Number and the percentage of piglets having SN titers  $\geq$  1:32 (log<sub>2</sub> titer=5)

S/P ratio		Co	Control		400MOS		800MOS	
$\geq$ I:32 (log <sub>2</sub> titer = 5)		(23/	(23/58) 40ª		(55/81) 68 <sup>b</sup>		oc (38/73) 52 <sup>ac</sup>	
Different	superscript	letters	in	the	same	row	indicate	significant
(P<0.05).								

The percentage of the piglets having SN titers  $\geq 1:32$  (log<sub>2</sub> titer=5) in 400MOS group was significantly higher (P<0.05) than that of the control group (Table 3). The value of the 800MOS group was higher than control group however with no statistically significant. No significant difference was seen in the S/P ratio and the SN titers of the big and small piglets of the three groups (data not shown).

#### DISCUSSION

The piglets fed with colostrum from the sows fed MOS in feed showed higher PRRS specific antibodies, which was demonstrated by the increase of the ELISA S/P ratio and SN titers (Table 1 and 2). The mechanisms of this phenomenon could be explained as follows; One month prepartum, serum PRRS-specific antibody of the sows translocate into the mammary gland probably by FcRn receptor (Salmon et al., 2009). IgG gradually accumulates in the mammary gland and reaches the plateu at the end of gestation. After parturition, piglets receive all IgG from the colostrum within 24 hours (Klopfenstein et al., 2006). The benefit of piglets having higher PRRSspecific antibody is that their maternally derived antibodies would persist longer and in high level in the blood stream compare to piglets having lower PRRSspecific antibody.

Due to dose dependent property of MOS in immune stimulation (Nochta *et al.*, 2009), 400 ppm MOS as feed additive for sows were effective to cause the enhancement of PRRS-specific antibodies (by ELISA S/P ratio; Table 1) whereas significant increase of neutralizing antibody was detected at dose higher than 400 ppm (Table 2). The number of piglets having SN titers >1:32 (log<sub>2</sub> titer=5) which assure at least 50% sterile immunity to PRRSV in piglets (Lopez *et al.*, 2007) was significantly increase at 400 ppm MOS in sows' feed. However, no significance increased was found at 800 ppm MOS. Taken together, the result indicates that the appropriate dose should be between 400 and 800 ppm, which needed to be explored further. **Conclusions:** Our results suggest that supplementation of MOS in sows' feed would be helpful to strengthen the effect of PRRS vaccination.

Acknowledgments: The authors would like to thank Division of Research Administration, Khon Kaen University and the Faculty of Veterinary Medicine, Khon Kaen University for supporting writing camp project. We also appreciate Prof. Yukufumi Nawa, Mr. James Michael Leahy, Assoc. Prof. Prasarn Tangkawattana and Assist. Prof. Chaiyapas Thamrongyoswittayakul for manuscript preparation.

# REFERENCES

- Charerntantanakul W, 2012. Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects.World J Virol, 1:23-30.
- Che TM, Johnson RW, Kelley KW, Van Alstine WG, Dawson KA, Moran CA and Pettigrew JE, 2011. Mannan oligosaccharide improves immune responses and growth efficiency of nursery pigs experimentally infected with porcine reproductive and respiratory syndrome virus. J Anim Sci, 89: 2592-2602.
- Geldhof MF, Vanhee M, van Breedam W, van Doorsselaere J, Karniychuk UU and Nauwynck HJ, 2012. Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial

vaccines against homologous and heterologous challenges. BMC Vet Res, 8: 182.

- Klopfenstein C, Farmer C and Martineau GP, 2006. Diseases of the Mammary Gland, In: Diseases of Swine (Straw BE, JJ Zimmerman, S D'Allaire, and DJ Taylor, eds): Blackwell Publishing, pp: 57-85.
- Lopez OJ, Oliveira MF, Garcia EA, Kwon BJ, Doster A and Osorio FA, 2007. Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent. Clin Vaccine Immunol, 14: 269-275.
- Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, Green AL and Zimmerman JJ, 2005. Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc, 3: 385-392.
- Nochta I, Tuboly T, Halas V and Babinszky L, 2009. Effect of different levels of mannan-oligosaccharide supplementation on some immunological variables in weaned piglets. J Anim Physiol An N, 93: 496-504.
- Osorio FA, Galeota JA, Nelson E, Brodersen B, Doster A, Wills R, Zuckermann F and Laegreid WW, 2002. Passive transfer of virusspecific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity. Virology, 302: 9-20.
- Salmon H, Berri M, Gerdts V and Meurens F, 2009. Humoral and cellular factors of maternal immunity in swine. Dev Comp Immunol, 33: 384-393.
- Zanello G, Meurens F, Serreau D, Chevaleyre C, Melo S, Berri M, D'Inca R, Auclair E and Salmon H, 2013. Effects of dietary yeast strains on immunoglobulin in colostrum and milk of sows. Vet Immunol Immunopathol, 152: 20-27.